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Gene mutations in the virulence regulator CovR/S of group 
A Streptococcus play a substantial role in the pathogenesis 
of streptococcal toxic shock syndrome. We screened 25 
group B Streptococcus (GBS) isolates obtained from pa-
tients with streptococcal toxic shock syndrome and found 
only 1 GBS clone harboring this kind of mutation. 
Streptococcal toxic shock syndrome (STSS) is typically caused by Streptococcus pyogenes (group A Strepto-
coccus [GAS]) (1). Major investigations on host-pathogen 
interactions have been performed to determine why some 
persons experience uncomplicated pharyngitis, but STSS 
develops in others. On a molecular level, mutations in covS 
(a sensor gene of the major virulence regulator CovR/S) 
have been frequently associated with invasive GAS disease 
(2). In 2009, we reported a case of STSS caused by S. aga-
lactiae (group B Streptococcus [GBS]) and covS mutation 
(3). Here, we reassess those findings in a larger collection 
of GBS isolates causing STSS.
We tested 26 GBS isolates from 25 patients (22 adults, 
3 children) (Table) that were pooled from 3 countries; the 
United States (22 strains collected 2004–2005), Germany 
(1 strain, 2006), and Switzerland (2 strains, 2005). For 1 
of the 2 case-patients from Switzerland, 2 isolates (same 
clone) were available for mutation analyses (patient 23 
[4]). The isolate from our previously published case report 
(Sweden, 2005 [3]) served as a control strain for molecu-
lar analyses; the corresponding case-patient was included 
in the demographic analyses (i.e., 26 patients: 23 adults, 
3 children). The median age of the included adult patients 
was 59 years (interquartile range 45.5–68 years); mortality 
rate was 35% (8/23). The ages of the 3 children were 0, 30, 
and 60 days (1 death).
We used standard molecular biology techniques for 
nucleic acid preparation and analysis. We performed mo-
lecular typing by multilocus sequence typing (MLST) as 
described (5) and capsular typing by using latex agglutina-
tion and PCR serotype determination (6) (Table). To ana-
lyze the cov gene locus, we amplified the genes covS and 
covR by PCR (online Appendix Table, http://wwwnc.cdc.
gov/EID/article/22/12/16-1063-Techapp1.pdf). Resulting 
PCR products underwent DNA sequencing with internal 
cov primers on an ABI PRISM 310 Genetic Analyzer (Ap-
plied Biosystems, Weiterstadt, Germany).
Nucleotide sequence analysis showed that, in 1 of 
the strains (from patient 18), both genes, the sensor his-
tidine kinase covS and the response regulator covR, had 
mutated. In covR, at nucleotide position 242, cytosine was 
replaced by thymine, leading to an amino acid exchange 
from alanine to valine. In addition, the covS gene of this 
strain showed a 1-bp deletion of adenine at position 895 of 
the gene, causing a frame shift and leading to a truncated 
CovS with a stop codon at nucleotide position 926 of the 
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gene. In the control strain that harbored a 3-bp deletion, 
our previously published finding was confirmed (3). In the 
remaining strains, cov alleles matched the gene sequences 
of completely sequenced GBS strains in the GenBank data-
base (NEM316, 2603V/R, 909A).
During the past few decades, the overall incidence of 
invasive GBS infections has increased substantially. This 
trend is particularly noticeable in the elderly and in persons 
with co-morbid conditions (7). Our results regarding age 
distribution of patients, mortality rate, and frequencies of 
different GBS serotypes are in line with results of previous 
studies. Twelve (52%) of 23 patients were >59 years old. 
The mortality rate for group B STSS (>30%) was similar to 
that reported for group A STSS (1). In a previous case series, 
which included 13 patients with group B STSS, the mortality 
rate was 23% (3/13) (8). Three-quarter of our strains (19/26 
strains) were attributed to serotype V or Ia/Ib. Large epide-
miologic studies have frequently implicated serotype s Ia/Ib, 
III, and V GBS isolates in the etiology of invasive disease in 
adults (9). Apart from sequence type (ST) 1 and ST23 (15/26 
strains), the distribution of MLSTs among the GBS isolates 
was heterogeneous. The highly virulent GBS lineage ST17 
was found in only 2 patients (1 adult and 1 child).
The role of covR/S mutations in the switch from col-
onization to invasion has been demonstrated for GAS in 
a mouse model (2). Consistent with these findings, GAS 
strains isolated from STSS patients frequently carry muta-
tions in this operon (10). Similarly, a 3-bp deletion in the 
covR gene was detected in a GBS strain that caused STSS 
and necrotizing fasciitis (3). However, our investigations 
on a larger collection of GBS isolates did not confirm a high 
cov mutation rate. Only 1 of 25 GBS clones demonstrated 
a mutation. From 1 patient, a colonizing and invasive iso-
late (same clone) was available (4); that isolate showed no 
mutation in covR/S.
Our results should be interpreted with caution because 
the absolute number of included patients is small, and the 
cases were pooled from various centers. Nonetheless, Ikebe 
et al. found covR/S mutations in 76 (46.3%) of 164 GAS 
strains causing STSS and in only 1.7% of 59 strains with-
out invasive disease (10). In light of these results, the low 
frequency of mutations found in our collection is surpris-
ing. Yet, the association with covR/S mutations and GBS 
TSS in a case report has been shown previously and con-
firmed here. However, GBS harbors multiple 2-component 
systems and stand-alone regulators. Our findings indicate 
that different virulence regulators may be involved in the 
pathogenesis of fulminant GBS disease.
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Table. GBS isolates collected from patients with STSS, showing results of capsular and multilocus sequence typing* 
Patient no. Isolate no. Patient age Outcome Capsular serotype Sequence type covR/S mutation 
1 BSU286 65 y Died II 22 – 
2 BSU287 71 y Survived Ia 23 – 
3 BSU288 46 y Died V 1 – 
4 BSU289 46 y Survived IV 397 – 
5 BSU290 43 y Survived V 1 – 
6 BSU291 35 y Died III 19 – 
7 BSU292 76 y Survived V 1 – 
8 BSU293 48 y Survived Ia 23 – 
9 BSU294 61 y Died V 1 – 
10 BSU295 45 y Survived V 1 – 
11 BSU296 63 y Died Ib 8 – 
12 BSU297 0 d Survived Ia 23 – 
13 BSU298 70 y Survived V 1 – 
14 BSU299 60 y Survived V 1 – 
15 BSU300 73 y Survived V 1 – 
16 BSU301 66 y Died III 17 – 
17 BSU302 2 mo Survived III 17 – 
18 BSU303 94 y Survived V 23 Yes 
19 BSU304 1 mo Died Ia 23 – 
20 BSU305 34 y Survived V 1 – 
21 BSU306 59 y Survived IV 2 – 
22 BSU307 79 y Died Ia 88 – 
23 (4) BSU865, VS 38 y Survived II 19 – 
 BSU866, BC   – – – 
24 BSU869 32 y Died Ib 8 – 
25 BSU870 53 y Survived Ia 23 – 
Control (3) BSU871 50 y Survived Ib 8 Yes 
*BC, blood culture; GBS, group B Streptococcus; STSS, streptococcal toxic shock syndrome; VS, vaginal swab; –, not found. 
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We report the characterization of a novel reassortant influ-
enza A(H1N2) virus not previously reported in humans. Re-
covered from a a pig farm worker in southeast Brazil who 
had influenza-like illness, this virus is a triple reassortant 
containing gene segments from subtypes H1N2 (hemagglu-
tinin), H3N2 (neuraminidase), and pandemic H1N1 (remain-
ing genes).
Influenza A(H1N2) viruses have been described in hu-man, avian, and especially swine populations over many 
years (1,2). In contrast to the widespread circulation of sea-
sonal H1N1 and H3N2 viruses, subtype H1N2 has been ob-
served only sporadically in humans (1,3–7). Human H1N2 
infections were reported during 1988–89 from sporadic 
cases over the winter in China (3). In 2000, another H1N2 
subtype strain emerged in the human population and be-
came widespread in Europe, with sporadic cases reported 
in the Middle East, Asia, Africa, and the Americas dur-
ing 2001–2003 (1,4). In Brazil, this H1N2 subtype strain 
was detected in humans in the southeast region during the 
winter of 2002 and in the northern region at the beginning 
of 2003 (5). This 2000–2003 H1N2 subtype strain had a 
genetic origin similar to the 1988–1989 H1N2 strain from 
China, both reassortants between human seasonal H1N1 
and H3N2 subtype lineages (3,4). 
In contrast, sporadic cases of zoonotic human infec-
tions with swine-origin H1N2 subtype variants (H1N2v) 
have also been described (6,7). In Brazil, the passive moni-
toring of influenza A viruses in pigs has taken place since 
2009 (8). Recently, a phylogenetic study revealed that 
H1N2 subtype viruses have circulated undetected in swine 
herds in Brazil for more than a decade, and reassortments 
may have occurred (9). These viruses seem to be reas-
sortants originating from an ancestor virus introduced to 
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